Selected article for: "acute lung injury and lung therapy"

Author: Merz, Tamara; Denoix, Nicole; Wepler, Martin; Gäßler, Holger; Messerer, David A. C.; Hartmann, Clair; Datzmann, Thomas; Radermacher, Peter; McCook, Oscar
Title: H(2)S in acute lung injury: a therapeutic dead end(?)
  • Cord-id: 0fg7270u
  • Document date: 2020_12_18
  • ID: 0fg7270u
    Snippet: This review addresses the plausibility of hydrogen sulfide (H(2)S) therapy for acute lung injury (ALI) and circulatory shock, by contrasting the promising preclinical results to the present clinical reality. The review discusses how the narrow therapeutic window and width, and potentially toxic effects, the route, dosing, and timing of administration all have to be balanced out very carefully. The development of standardized methods to determine in vitro and in vivo H(2)S concentrations, and the
    Document: This review addresses the plausibility of hydrogen sulfide (H(2)S) therapy for acute lung injury (ALI) and circulatory shock, by contrasting the promising preclinical results to the present clinical reality. The review discusses how the narrow therapeutic window and width, and potentially toxic effects, the route, dosing, and timing of administration all have to be balanced out very carefully. The development of standardized methods to determine in vitro and in vivo H(2)S concentrations, and the pharmacokinetics and pharmacodynamics of H(2)S-releasing compounds is a necessity to facilitate the safety of H(2)S-based therapies. We suggest the potential of exploiting already clinically approved compounds, which are known or unknown H(2)S donors, as a surrogate strategy.

    Search related documents:
    Co phrase search for related documents
    • acute lung injury and adaptive response: 1, 2, 3, 4, 5, 6
    • acute lung injury and administration route: 1
    • acute lung injury and administration timing: 1, 2, 3
    • acute lung injury model and administration route: 1
    • acute phase and adaptive response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and administration route: 1, 2
    • adaptive response and administration route: 1, 2, 3